Moderna
MRNA
About: Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Employees: 5,800
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
3.1% more ownership
Funds ownership: 72.23% [Q1] → 75.33% (+3.1%) [Q2]
9% more repeat investments, than reductions
Existing positions increased: 233 | Existing positions reduced: 213
2% more capital invested
Capital invested by funds: $7.9B [Q1] → $8.04B (+$141M) [Q2]
7% less first-time investments, than exits
New positions opened: 91 | Existing positions closed: 98
3% less funds holding
Funds holding: 681 [Q1] → 662 (-19) [Q2]
14% less funds holding in top 10
Funds holding in top 10: 7 [Q1] → 6 (-1) [Q2]
18% less call options, than puts
Call options by funds: $896M | Put options by funds: $1.09B
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
Leerink Partners
Mani Foroohar
|
$15
|
Underperform
Maintained
|
22 Aug 2025 |
|
Barclays
Gena Wang
|
$31
|
Equal-Weight
Maintained
|
4 Aug 2025 |
|
B of A Securities
Dimple Gosai
|
$25
|
Underperform
Maintained
|
22 Jul 2025 |
Financial journalist opinion
Based on 23 articles about MRNA published over the past 30 days
